GMAB - Seagen Genmab update Phase 3 data for uterine cancer therapy
2023-10-23 14:58:57 ET
More on Genmab, Seagen, etc.
- Zai Lab Stock: De-Risking Through Market Tapping
- Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors
- Genmab Is Down To Attractive Levels
- Seagen/ Astellas succeed in Phase 3 trial for bladder cancer therapy
- Seagen ticks higher as EU approves $43B sale to Pfizer
For further details see:
Seagen, Genmab update Phase 3 data for uterine cancer therapy